A report has been published analyzing Japan’s topical analgesics market from 2026 to 2035, including market size and growth rates, key formulation types, sales channels and company trends. It outlines the current situation, future outlook and key growth drivers.
Japan’s topical analgesics market is estimated at approximately $540.92 million in 2025 and is expected to expand at a compound annual growth rate of 4.9% from 2026 to 2035, reaching approximately $872.75 million by 2035. Key growth factors include population aging, the increasing prevalence of arthritis and musculoskeletal disorders, demand from consumers seeking to avoid oral medications, a preference for localized and non-invasive pain management, and advances in formulation technology.
Topical analgesics are applied to the skin in a variety of dosage forms, including creams, ointments, gels, patches and sprays. They are characterized by their ability to address localized pain while limiting systemic exposure. Ease of use is particularly valued among older people, and demand for treatment focused on the affected area remains strong. A key driver is the rising number of arthritis patients. Estimates for 2024 put the number of people with rheumatoid arthritis in Japan at approximately 825,000.
Non-opioid formulations are expected to lead the market and include diclofenac, ibuprofen, naproxen, acetaminophen, lidocaine and capsaicin. Demand for non-opioid products, driven in part by concerns about opioid misuse, is one factor supporting the market, while advances in transdermal delivery technology and nanotechnology are also attracting attention as key market themes.
By formulation, creams and ointments are expected to remain the largest category. Gels are expected to continue growing because of their feel and absorption characteristics, while patches are considered particularly important in the Japanese market. Tubes are expected to account for the largest share by packaging format. Distribution channels include hospital pharmacies, retail pharmacies and online pharmacies. Online pharmacies are forecast to drive the market, although their current share is considered unclear. Demand is strongest in urban areas, while population aging and demand for self-care at home support demand in regional areas.
Japanese companies’ overseas expansion is prominent, with Hisamitsu Pharmaceutical among the companies marketing topical analgesic brands, including Salonpas, both in Japan and overseas. Competition in the topical analgesics market is centered on Kobayashi Pharmaceutical, Haleon, Bayer and Hisamitsu Pharmaceutical, along with Johnson & Johnson, Pfizer, Sanofi, Reckitt Benckiser, Novartis and Taiho Pharmaceutical. Overall, from 2025 to 2035, areas such as non-opioid products, creams, gels, patches and transdermal delivery are expected to remain central to the market, which is expected to develop toward high-functionality topical pain management.